ReviewTherapeutics and clinical risk management2023

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.

Dimitrios D Raptis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.